Physician profile
Donald E Lamarche
NPI 1639269376
$17,227.65
in general payments reported to CMS, 2019-2025
44 companies · $2,366 in 2025
The $2,366 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,075 · 2020: $1,432 · 2021: $2,568 · 2022: $2,987 · 2023: $2,399 · 2024: $2,401 · 2025: $2,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,048 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,048.32 |
| Education | $117.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,106.43 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Alexion Pharmaceuticals, INC. | $1,815.35 | 2019-2025 | Ultomiris |
| Genentech USA, INC. | $1,386.42 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Genzyme Corporation | $1,195.80 | 2019-2023 | |
| Abbvie INC. | $1,069.86 | 2019-2025 | |
| Ucb, INC. | $935.28 | 2019-2024 | Briviact, Rystiggo |
| Pfizer INC. | $776.49 | 2023-2025 | |
| Lundbeck LLC | $633.19 | 2019-2025 | Vyepti |
| Sk Life Science, INC. | $609.08 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $559.68 | 2019-2024 | Ajovy, Austedo Xr |
| Amgen INC. | $532.05 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $528.07 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $513.85 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $481.02 | 2021 | |
| Neurelis, INC. | $362.16 | 2022-2025 | Valtoco |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Lamarche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.